Stéphanie Forté: New Evidence Strengthens the Case for Hydroxyurea in HbSC Disease
Stéphanie Forté, Principal Researcher at the Innovation Hub at the CHUM Research Center (CRCHUM), shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in British Journal of Haematology, adding:
”Our Quebec study on hydroxyurea in SC disease (HbSC) has just been the subject of an editorial commentary in the British Journal of Haematology.
The message of the commentary is clear: HbSC disease is not a ‘mild’ form of sickle cell disease — it is a biologically distinct entity, long understudied and undertreated out of an abundance of caution.
Our results show a 56 percent reduction in vaso-occlusive crises with hydroxyurea initiation, without complications related to hyperviscosity — a historical fear in this population.
Interestingly, treatment discontinuations were mostly related to modifiable barriers (prescription renewal, education, follow-up) rather than toxicity.
A reminder that patient support is as important as pharmacology.”
Title: Hydroxyurea (hydroxycarbamide) use in adults with haemoglobin SC disease: A real-world study in Quebec
Authors: Alice Girard, Laurianne Charette, Mélissa Haouchine, Laurence Bozec, Mohamed Zakaria Bachir Bouyadjera, Mariane Poitras, Vincent-Thierry Taillefer, Chloé Trudeau, Yves Pastore, Nathalie Letarte, Stéphanie Forté
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 8, 2026, 11:15Andreas Tridimas: Atherosclerosis Is Greyer Than We Admit
-
Sep 8, 2026, 10:59Eman M. Elsabbagh: Pediatric Nonmalignant HCT Enters the Era of Precision Conditioning and Gene Therapy
-
Sep 8, 2026, 10:50Dena Winchester: Sponsored Genetic Testing Programs Improve Access for Children With Hemophilia A
-
Sep 8, 2026, 10:49Alessandra Bosch: Von Willebrand Disease and Rare Bleeding Disorders, Collaborative Insights and Patient Empowerment
-
Sep 8, 2026, 09:42Vineet Sankhla: Rethinking Potent P2Y12 Inhibition in AF Patients Undergoing PCI
-
Sep 8, 2026, 09:23Mehdi Mirsaeidi: Platelets and Thromboinflammation in COPD
-
Sep 8, 2026, 09:03Michel Cabrera Ortega: LAAC vs OAC – Which Risk Are We Trading?
-
Sep 8, 2026, 08:58Zehraan Ibni Akbar: Reading Blood Through the Peripheral Smear
-
Sep 8, 2026, 08:50Dirk Sibbing: Potent P2Y12 Inhibition in Patients With Atrial Fibrillation and Acute Coronary Syndrome